Cancer News and Research

Latest Cancer News and Research

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Men with type 1 diabetes could grow their own insulin-producing cells from testicular tissue, says GUMC

Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say Georgetown University Medical Center (GUMC) researchers who presented their findings today at the American Society of Cell Biology 50th annual meeting in Philadelphia.

13 Dec 2010

High CTC level found to be early marker of poor outcome in metastatic breast cancer

A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy.

13 Dec 2010

Genetic changes in HDAC9 gene may modulate onset of ER positive breast cancer and its recurrence

Investigators at The Cancer Institute of New Jersey have presented new research at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. Their work highlights how a variation in a person's DNA sequence is associated with an earlier age of onset for breast cancer that is stimulated by the hormone estrogen (estrogen receptor positive).

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Access announces $6.0 million registered direct offering

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.

10 Dec 2010

OpEds: Palin on the Ryan Roadmap, Seniors and primary care docs, Arizona transplant controversy

[The president's National Commission on Fiscal Responsibility and Reform's report] implicitly endorses the use of 'death panel'-like rationing by way of the new Independent Payments Advisory Board—making bureaucrats, not medical professionals, the ultimate arbiters of what types of treatment will (and especially will not) be reimbursed under Medicare.

10 Dec 2010

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.

10 Dec 2010

Weightlifting may help prevent lymphedema following breast cancer treatment

Weightlifting may play a key role in the prevention of the painful limb-swelling condition lymphedema following breast cancer treatment, according to new research from the University of Pennsylvania School of Medicine. Combined with the team's previous findings that the exercise limits a worsening of symptoms among women who already have lymphedema, the new data cements the reversal of long-running advice that breast cancer survivors should avoid lifting anything heavier than five pounds after they finish treatment.

10 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

HRT with estrogen alone may reduce risk of breast cancer: Study

While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk, according to study results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

10 Dec 2010

Complete Genomics announces CNV and SV results as part of complete human genome sequencing service

Complete Genomics Inc. announced today that its customers will now receive copy number variation (CNV) and structural variation (SV) results as part of the CGA™ Service. This new enhancement includes additional types of variation data including quantitative, large-scale copy number measurements and larger inter- and intrachromosomal rearrangements.

10 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Elekta K.K., a wholly owned subsidiary of Elekta AB, has entered into a sales and marketing agreement with Toshiba Medical Systems Corporation in Japan.

From Elekta 10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its RIGS® technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe's efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.

10 Dec 2010

Simple molecular sensor color test to determine safe fluoride levels

Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer - a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.

10 Dec 2010

Cancer News and Research

Latest Cancer News and Research

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Men with type 1 diabetes could grow their own insulin-producing cells from testicular tissue, says GUMC

High CTC level found to be early marker of poor outcome in metastatic breast cancer

Genetic changes in HDAC9 gene may modulate onset of ER positive breast cancer and its recurrence

Depression drug appears effective in reducing pain associated with breast cancer treatment

Access announces $6.0 million registered direct offering

OpEds: Palin on the Ryan Roadmap, Seniors and primary care docs, Arizona transplant controversy

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Weightlifting may help prevent lymphedema following breast cancer treatment

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

HRT with estrogen alone may reduce risk of breast cancer: Study

Complete Genomics announces CNV and SV results as part of complete human genome sequencing service

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

FDA grants Neoprobe Type B pre-IND meeting for RIGS technology BLA

Simple molecular sensor color test to determine safe fluoride levels

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in